These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

250 related items for PubMed ID: 1424938

  • 1. Pathogenesis and management of acute heart failure and cardiogenic shock: role of inotropic therapy.
    McGhie AI, Golstein RA.
    Chest; 1992 Nov; 102(5 Suppl 2):626S-632S. PubMed ID: 1424938
    [Abstract] [Full Text] [Related]

  • 2. Inotropic therapy for cardiac low output syndrome: comparison of hemodynamic effects of dopamine/dobutamine versus dopamine/dopexamine.
    El Mokhtari NE, Arlt A, Meissner A, Lins M.
    Eur J Med Res; 2007 Nov 05; 12(11):563-7. PubMed ID: 18024265
    [Abstract] [Full Text] [Related]

  • 3. Right ventricular function in myocardial infarction complicated by cardiogenic shock: Improvement with levosimendan.
    Russ MA, Prondzinsky R, Carter JM, Schlitt A, Ebelt H, Schmidt H, Lemm H, Heinroth K, Soeffker G, Winkler M, Werdan K, Buerke M.
    Crit Care Med; 2009 Dec 05; 37(12):3017-23. PubMed ID: 19661807
    [Abstract] [Full Text] [Related]

  • 4. Intravenous thyroid hormone supplementation in heart failure with cardiogenic shock.
    Malik FS, Mehra MR, Uber PA, Park MH, Scott RL, Van Meter CH.
    J Card Fail; 1999 Mar 05; 5(1):31-7. PubMed ID: 10194658
    [Abstract] [Full Text] [Related]

  • 5. Dobutamine and nitroprusside infusion in patients with severe congestive heart failure: hemodynamic improvement by discordant effects on mitral regurgitation, left atrial function, and ventricular function.
    Capomolla S, Pozzoli M, Opasich C, Febo O, Riccardi G, Salvucci F, Maestri R, Sisti M, Cobelli F, Tavazzi L.
    Am Heart J; 1997 Dec 05; 134(6):1089-98. PubMed ID: 9424070
    [Abstract] [Full Text] [Related]

  • 6. Pharmacologic support in cardiogenic shock.
    Rude RE.
    Adv Shock Res; 1983 Dec 05; 10():35-49. PubMed ID: 6349299
    [Abstract] [Full Text] [Related]

  • 7. Haemodynamic advantages of a combined inotropic/venodilator regimen over inotropic monotherapy in acute heart failure.
    Verma SP, Silke B, Nelson GI, Hussain M, Richmond A, Taylor SH.
    J Cardiovasc Pharmacol; 1985 Dec 05; 7(5):943-7. PubMed ID: 2413305
    [Abstract] [Full Text] [Related]

  • 8. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock.
    Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Söffker G, Lemm H, Swyter M, Wegener N, Winkler M, Carter JM, Reith S, Werdan K, Buerke M.
    Crit Care Med; 2007 Dec 05; 35(12):2732-9. PubMed ID: 17893627
    [Abstract] [Full Text] [Related]

  • 9. [Therapy of cardiogenic shock with dobutamine and nitroglycerin].
    Bussmann WD, Wehrheim HG.
    Dtsch Med Wochenschr; 1983 Aug 26; 108(34):1273-80. PubMed ID: 6411441
    [Abstract] [Full Text] [Related]

  • 10. Dobutamine-norepinephrine, but not vasopressin, restores the ventriculoarterial matching in experimental cardiogenic shock.
    How OJ, Røsner A, Kildal AB, Stenberg TA, Gjessing PF, Hermansen SE, Myrmel T.
    Transl Res; 2010 Nov 26; 156(5):273-81. PubMed ID: 20970750
    [Abstract] [Full Text] [Related]

  • 11. Cardiogenic shock.
    Rackley CE, Russell RO, Mantle JA, Rogers WJ.
    Cardiovasc Clin; 1981 Nov 26; 11(3):15-24. PubMed ID: 7214388
    [Abstract] [Full Text] [Related]

  • 12. Hemodynamic effects of sulmazol (ARL-115 BS), a new vasodilator and positive inotropic agent, in patients with cardiogenic shock.
    Simoons ML, Muskens G, Hugenholtz PG.
    Herz; 1983 Feb 26; 8(1):34-40. PubMed ID: 6832691
    [Abstract] [Full Text] [Related]

  • 13. Hemodynamic and therapeutic effects of intravenous dopamine.
    Théroux P, Mizgala HF, Bourassa MG.
    Can Med Assoc J; 1977 Mar 19; 116(6):645-8. PubMed ID: 608165
    [Abstract] [Full Text] [Related]

  • 14. Inotropic therapy for cardiac low output syndrome: comparison of hemodynamic effects of dopamine/dobutamine versus dopamine/dopexamine.
    El Mokhtari NE, Arlt A, Meissner A, Lins M.
    Eur J Med Res; 2008 Oct 27; 13(10):459-63. PubMed ID: 19008172
    [Abstract] [Full Text] [Related]

  • 15. Dobutamine in severe scorpion envenomation: effects on standard hemodynamics, right ventricular performance, and tissue oxygenation.
    Elatrous S, Nouira S, Besbes-Ouanes L, Boussarsar M, Boukef R, Marghli S, Abroug F.
    Chest; 1999 Sep 27; 116(3):748-53. PubMed ID: 10492282
    [Abstract] [Full Text] [Related]

  • 16. Initiation of ivabradine in cardiogenic shock.
    Chiu MH, Howlett JG, Sharma NC.
    ESC Heart Fail; 2019 Oct 27; 6(5):1088-1091. PubMed ID: 31332966
    [Abstract] [Full Text] [Related]

  • 17. Mechanical versus pharmacologic support for cardiogenic shock.
    Dhar G, Jolly N.
    Catheter Cardiovasc Interv; 2010 Mar 01; 75(4):626-9. PubMed ID: 20049971
    [Abstract] [Full Text] [Related]

  • 18. Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failure.
    Viquerat CE, Kereiakes D, Morris DL, Daly PA, Wexman M, Frank P, Parmley WW, Chatterjee K.
    J Am Coll Cardiol; 1985 Feb 01; 5(2 Pt 1):326-32. PubMed ID: 3155761
    [Abstract] [Full Text] [Related]

  • 19. [Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine].
    Meissner A, Schmelzle T, Simon R.
    Z Kardiol; 1996 Nov 01; 85(11):839-46. PubMed ID: 9064946
    [Abstract] [Full Text] [Related]

  • 20. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK?
    Menon V, White H, LeJemtel T, Webb JG, Sleeper LA, Hochman JS.
    J Am Coll Cardiol; 2000 Sep 01; 36(3 Suppl A):1071-6. PubMed ID: 10985707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.